Pivmecillinam Treatment of Community-Acquired Uncomplicated Pyelonephritis Based on Sparse Data
Journal: Global Journal of Infectious Diseases and Clinical Research (Vol.1, No. 1)Publication Date: 2015-11-20
Authors : Filip Jansaker Frederik Boetius Hertz Niels Frimodt-Moller; Jenny Dahl Knudsen;
Page : 014-017
Keywords : Pivmecillinam; Antimicrobial therapy; Pyelonephritis; Community-acquired infections; Old antibiotics;
Abstract
Background: Pivmecillinam has good pharmacokinetic properties for treatment of infections in the urinary tract, and the mecillinam resistance rate in Enterobacteriaceae is very low. In a European guideline pivmecillinam is recommended as a first-line drug for treatment of lower urinary tract infections. In Danish and Norwegian guidelines pivmecillinam is also recommended for acute uncomplicated pyelonephritis, although with very sparse documentation of effect.
Other Latest Articles
- Prevalence and Antimicrobial-Resistance of Staphylococcus aureus Isolated from Blood Culture in University Hospital, Turkey
- Quorum Sensing in Bacterial Pathogenesis
- Sero-Prevalence of Hepatitis B and Hepatitis C Viruses among Tuberculosis Patients in Kassala, Eastern Sudan
- Variation in morpho-physiological characters of four lentil genotypes of Bangladesh
- Camel production in Kingdom of Saudi Arabia: Economic and environmental impacts
Last modified: 2018-09-12 13:44:04